Our investigations revealed a MNK-controlled mechanism acting on mTORC2-AKT.

Herein, a structure-based virtual screening approach was performed to identify potential MNK inhibitors from natural products.

Compound 23 is the first highly selective dual MNK inhibitor targeting dysregulated translation being assessed clinically.

The hit compounds display activity in Mnk biochemical and cellular assays, including acute myeloid leukemia progenitors.

MNK-795 would have to be taken only once a day unlike other generic combinations in the market.

Mutations in ATP7A can lead to the usually lethal Menkes disease.

Menkes disease is a very rare X-linked copper metabolism disorder that results from an ATP7A gene mutation.

Rapid diagnosis of Menkes disease and early start of copper therapy is critical for the effectiveness of treatment.

With the advent of subcutaneous copper-histidine therapy, the early diagnosis of Menkes disease becomes of utmost importance for patients' prognosis.

Menkes disease is an X-linked recessive inherited disease caused by pathogenic variants in ATP7A, which leads to profound copper deficiency.

The neuropathologic abnormalities in three new cases of Menkes' kinky hair disease are described.